BNTC News

Antavo Global Customer Loyalty Report: More Than a Quarter of US Loyalty Programme Points Go Unspent With an Estimated $10 Billion in Savings Lost Annually

Benitec Biopharma Provides Positive Long-Term Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial Demonstrating Robust Efficacy and Continued Durability of Response

Benitec Biopharma Releases First Quarter 2026 Financial Results and Provides Operational Update

Benitec Biopharma Inc. Announces Pricing of $100 Million Common Stock Offering

Benitec Biopharma Inc. Announces Proposed Public Offering

Benitec Biopharma Provides Positive Interim Clinical Study Results for BB-301 Phase 1b/2a Clinical Trial and Receives FDA Fast Track Designation for BB-301

Benitec Biopharma Announces Appointment of Sharon Mates Ph.D. to its Board of Directors

Benitec Biopharma to Provide Phase 1b/2a Clinical Study Update for BB-301 in Oculopharyngeal Muscular Dystrophy